Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AIDSVAX B/E and MVA/HIV62B Late Boost in HVTN 205 Participants
NCT02852005Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Jan 2017
- Primary completion
- Aug 2018
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of AIDSVAX B/E in human immunodeficiency virus infection (HIV) (5 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Local Reactogenicity Signs and Symptoms, Systemic Reactogenicity Signs and Symptoms and 6 more. Started Jan 2017; status: completed.
02
Drugs
AIDSVAX B/E
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT02852005.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02852005.